½ÃÀ庸°í¼­
»óǰÄÚµå
1679591

µ¿¹°¿ë ¾à¹°°¨½Ã ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­(2025-2030³â) : ¼Ö·ç¼Çº°, À¯Çüº°, Á¦Ç° À¯Çüº°, µ¿¹° À¯Çüº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø

Veterinary Pharmacovigilance Market Size, Share & Trends Analysis Report By Solution (Software, Services), By Type (In-house), By Product (Anti-Infective) By Animal Type (Dogs, Cats), By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

µ¿¹°¿ë ¾à¹°°¨½Ã ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è µ¿¹°¿ë ¾à¹°°¨½Ã ½ÃÀå ±Ô¸ð´Â 2025-2030³â¿¡ °ÉÃÄ 13.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ Àü¸ÁÀ̸ç, 2030³â±îÁö 19¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº µ¿¹°ÀÇ ÀǾàǰ ºÎÀÛ¿ë ¹ß»ý·ü Áõ°¡, ¹Ý·Áµ¿¹°ÀÇ ¼ö Áõ°¡, µ¿¹° À¯·¡ ½Äǰ ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ±ÔÁ¦ ´ç±¹ÀÇ ¸ð´ÏÅ͸µ °­È­¿Í ¾ö°ÝÇÑ ¾ÈÀü ±âÁØÀÇ Çʿ伺À¸·Î »õ·Î¿î ¾à¹°°¨½Ã ±â¼ú°ú ÅøÀÇ °³¹ßµµ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Accenture´Â ICSR »ç·Ê ó¸®, VeDDRA ÄÚµù, ½ÅÈ£ °ËÃâ, ¹®Çå °ü¸®, EvVetMPD Áö¿ø ¹× ±ÔÁ¦ Á¤º¸¸¦ Æ÷ÇÔÇÑ µ¿¹°¿ë ¾à¹°°¨½Ã ¼­ºñ½º ¼¼Æ®¸¦ Á¦°øÇÕ´Ï´Ù. Áý°è º¸°í, ½Å¼ÓÇÑ º¸°í, ½ÅÈ£ °ü¸®¿¡ ´ëÇÑ »ê¾÷ ¿ä±¸ Áõ°¡°¡ ¾ÕÀ¸·Î ¼ö³â°£ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

COVID-19ÀÇ À¯ÇàÀº µ¿¹° ÀǾàǰ ½ÃÀå¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâ°ú ±àÁ¤ÀûÀÎ ¿µÇâ ¸ðµÎ¸¦ °¡Á®¿Ô½À´Ï´Ù. COVID-19´Â °úÁ¦¸¦ ³ºÀº ÇÑÆí, ±â¾÷ÀÌ ÀûÀÀÇϰí Çõ½ÅÇÒ ±âȸµµ Á¦°øÇÏ¿´À¸¸ç, ¼¼°èÀÇ °Ç°­ À§±â ¼Ó¿¡¼­ µ¿¹°¿ë ÀǾàǰÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ¸ð´ÏÅ͸µÇÏ´Â °ÍÀÇ Á߿伺À» ºÎ°¢½ÃÄ×½À´Ï´Ù. ÀÌ´Â µ¿¹°¿ë ¾à¹°°¨½Ã ¼Ö·ç¼Ç¿¡ ´ëÇÑ Àνİú ä¿ëÀ» µÞ¹ÞħÇß½À´Ï´Ù. ÀÌ ºÎ¹®Àº µ¿¹° ÀÇ·á ½ÃÀåÀÇ ½ÅÈï ºÎ¹®ÀÔ´Ï´Ù. ÀÌ ºÎ¹®Àº µ¿¹°¿ë ÀǾàǰ, ¹é½Å ¹× ±âŸ µ¿¹°¿ë ÀǾàǰÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» ¸ð´ÏÅ͸µÇÏ°í ºÎÀÛ¿ëÀ̳ª »ç°í°¡ ¹ß»ýÇÒ °æ¿ì º¸°íÇÕ´Ï´Ù. µ¿¹° º¹Áö¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í µ¿¹° À¯·¡ ½Äǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ µû¶ó ÀÌ ½ÃÀåÀº ÃÖ±Ù ¸î ³â°£ Å« ÁÖ¸ñÀ» ¹Þ¾Æ¿Ô½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ ³ë·Âµµ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. 2018³â 6¿ù Medfiles´Â ÀϺ»¿¡ Áö»ç¸¦ ¼³¸³ÇÏ¿© À¯·´ ¹× ÀϺ» °í°´¿¡°Ô ´Ù¾çÇÑ ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ¿©±â¿¡´Â ¾à¹°°¨½Ã, ÀÓ»ó°Ë»ç, ºÐ¼® ¼­ºñ½º µîÀÌ Æ÷ÇԵ˴ϴÙ. 2022³â 2¿ù, ½ÃÀåÀÇ ÁÖ¿ä ÁøÃâ±â¾÷ÀÎ Ennov´Â ºÏ¹Ì ½ÃÀå¿¡¼­ÀÇ ¼º°øÀûÀÎ ¼ºÀå¿¡ ´ëÀÀÇϱâ À§ÇØ ¹Ì±¹¿¡ Áö»ç¸¦ ¼³¸³Çß½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¾à¹°°¨½Ã ´É·ÂÀÇ °­È­¿¡ ÁßÁ¡À» µÐ ȸ»çÀÇ ¼¼°è »ç¾÷ Àü°³ ¹üÀ§°¡ È®´ëµÇ¾ú½À´Ï´Ù. EnnovÀÇ ¾à¹°°¨½Ã ¼­ºñ½º¿¡´Â Àΰ£ ¹× µ¿¹° »ý¸í °úÇÐ ½ÃÀåÀÇ °í°´¿¡ ´ëÇÑ »ç·Ê ¼öÁý, ÁßÁõµµ ºÐ·ù, ½ÅÈ£ °¨Áö ¹× °ü¸®°¡ Æ÷ÇԵ˴ϴÙ.

µ¿¹°¿ë ¾à¹°°¨½Ã ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • µ¿¹°¿ë ¾à¹°°¨½Ã ½ÃÀåÀÇ ÁÖ¿ä µ¿Çâ Áß Çϳª´Â ÀüÀÚ º¸°í ½Ã½ºÅÛ ¹× µ¥ÀÌÅÍ ºÐ¼® µµ±¸¿Í °°Àº ½Å±â¼úÀÇ Ã¤ÅÃÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ºÎÀÛ¿ëÀ» º¸´Ù È¿À²ÀûÀ̰í Á¤È®ÇÏ°Ô ¸ð´ÏÅ͸µ °¡´ÉÇÏ°Ô Çϸç ÀáÀçÀûÀÎ ¾ÈÀü ¹®Á¦°¡ ½É°¢ÇØÁö±â Àü¿¡ ÆÄ¾ÇÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
  • ¼ÒÇÁÆ®¿þ¾î ºÎ¹®Àº ¼¼°èÀÇ µ¿¹°¿ë ¾à¹°°¨½Ã »ê¾÷À» Áö¹èÇϰí ÀÖÀ¸¸ç, 2024³â¿¡´Â 51.0%ÀÇ ÃÖ´ë ÆÇ¸Å Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • Á¦Ç°º°·Î Ç×°¨¿°Á¦´Â 2024³â 45.4% ÀÌ»óÀÇ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÇÑÆí, »ý¹°Á¦Á¦ ºÎ¹®Àº ÇâÈÄ ¼ö³â°£ 14%¸¦ ÃʰúÇÏ´Â ³ôÀº ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
  • ÀÚ»ç ºÎ¹®Àº 2024³â 54.4%ÀÇ ÃÖ´ë ¼öÀÍ Á¡À¯À²·Î ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù.
  • µ¿¹°¿ë ¾à¹°°¨½Ã »ê¾÷¿¡¼­´Â °³°¡ 2024³â¿¡ 50.0%ÀÇ ÃÖ°í ¼öÀÍ Á¡À¯À²À» ȹµæÇÏ¿© Áö¹èÀûÀÎ ÁöÀ§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
  • ºÏ¹Ì´Â 2024³â Áö¿ªº° ½ÃÀå Á¡À¯À²·Î ¾à 40%¸¦ Â÷ÁöÇÏ¸ç ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº 2025-2030³â¿¡ °ÉÃÄ 15.4% ÀÌ»óÀÇ °¡Àå ³ôÀº ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
  • µ¿¹°¿ë ¾à¹°°¨½Ã ½ÃÀåÀº Çõ½ÅÀ» ÀÏÀ¸ÄÑ Â÷º°È­¸¦ µµ¸ðÇÏ°í µ¿¹°¿ë ÀǾàǰ »ê¾÷ÀÇ ÁøÈ­ÇÏ´Â ¿ä±¸¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â ±â¾÷¿¡ Å« ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå µ¿¹°¿ë ¾à¹°°¨½Ã ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅëÀÇ Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ºñÁî´Ï½º ȯ°æ ºÐ¼®
    • »ê¾÷ ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTLE ºÐ¼®

Á¦4Àå µ¿¹°¿ë ¾à¹°°¨½Ã ½ÃÀå : ¼Ö·ç¼Çº° ºñÁî´Ï½º ºÐ¼®

  • ¼Ö·ç¼Çº° ½ÃÀå Á¡À¯À²(2024³â ¹× 2030³â)
  • ¼Ö·ç¼Ç ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, ¼Ö·ç¼Çº°(2018-2030³â)
  • ¼ÒÇÁÆ®¿þ¾î
  • ¼­ºñ½º

Á¦5Àå µ¿¹°¿ë ¾à¹°°¨½Ã ½ÃÀå : À¯Çüº° ºñÁî´Ï½º ºÐ¼®

  • À¯Çüº° ½ÃÀå Á¡À¯À²(2024³â ¹× 2030³â)
  • À¯Çü ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, À¯Çüº°(2018-2030³â)
  • »ç³»
  • °è¾à ¾Æ¿ô¼Ò½Ì

Á¦6Àå µ¿¹°¿ë ¾à¹°°¨½Ã ½ÃÀå : Á¦Ç°º° ºñÁî´Ï½º ºÐ¼®

  • Á¦Ç°º° ½ÃÀå Á¡À¯À²(2024³â ¹× 2030³â)
  • Á¦Ç° ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, Á¦Ç°º°(2018-2030³â)
  • »ý¹°Á¦Á¦
  • Ç×°¨¿°Á¦
  • ±âŸ

Á¦7Àå µ¿¹°¿ë ¾à¹°°¨½Ã ½ÃÀå : µ¿¹° À¯Çüº° ºñÁî´Ï½º ºÐ¼®

  • µ¿¹° À¯Çüº° ½ÃÀå Á¡À¯À²(2024³â ¹× 2030³â)
  • µ¿¹° À¯Çü ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, µ¿¹° À¯Çüº°(2018-2030³â)
  • °³
  • °í¾çÀÌ
  • ±âŸ µ¿¹° À¯Çü

Á¦8Àå µ¿¹°¿ë ¾à¹°°¨½Ã ½ÃÀå : Áö¿ªº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â ¹× 2030³â)
  • Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®(2018-2030³â)
  • ºÏ¹Ì
    • ±¹°¡º°(2018-2030³â)
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ±¹°¡º°(2018-2030³â)
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ±¹°¡º°(2018-2030³â)
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ±¹°¡º°(2018-2030³â)
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ±¹°¡º°(2018-2030³â)
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï ±¸µµ

  • Âü°¡ÀÚ °³¿ä
  • ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´× ºÐ¼®
  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ/»óÀå ±â¾÷
    • ArisGlobal
    • Accenture
    • Ennov
    • Sarjen Systems Pvt. Ltd.
    • Pharsafer Associates Limited
    • Knoell
    • Biologit
    • Indivirtus
    • Azierta Contract Science Support Consulting
    • Oy Medfiles Ltd.
CSM 25.04.17

Veterinary Pharmacovigilance Market Growth & Trends:

The global veterinary pharmacovigilance market size is expected to reach USD 1.91 billion by 2030, registering a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by several factors, including the increasing incidence of adverse drug reactions in animals, the rising adoption of companion animals, and the growing demand for animal-derived food products. Additionally, the increasing regulatory scrutiny and the need for stringent safety standards have led to the development of new pharmacovigilance technologies and tools. Accenture for instance, offers a range of Veterinary Vigilance services that include ICSR Case Processing , VeDDRA Coding, Signal Detection, Literature Management, EvVetMPD support, and Regulatory Intelligence. Growing industry requirements for aggregate reporting, expedited reporting, and management of signals are expected to propel the market growth in the coming years.

The COVID-19 pandemic has had both negative and positive impacts on the animal health market While it has created challenges, it has also created opportunities for companies to adapt and innovate, and has highlighted the importance of monitoring the safety and efficacy of animal health products in the context of global health crises. This supported the awareness and adoption of veterinary pharmacovigilance solutions. The field is an emerging sector within the animal healthcare market. It involves monitoring the safety and effectiveness of veterinary medicines, vaccines, and other animal health products, and reporting any adverse reactions or incidents that may occur. This information is then used to improve the safety and quality of these products and to protect animal health.With the growing concern for animal welfare and the increasing demand for animal-based food products, the market has gained significant attention in recent years.

Initiatives by key market participants is another factor fueling the market growth. In June 2018, Medfiles opened a new office in Japan to cater to European and Japanese clients with a range of services. These include pharmacovigilance, clinical trials, and analytical services, among others. In February 2022, Ennov, a key market player opened a new office in the U.S. in response to successful growth in the North American market. This expanded the company's global footprint with a focus on building its pharmacovigilance capabilities. Ennov's pharmacovigilance offerings include case intake, triage, signal detection and management for customers from human and veterinary life sciences market.

Veterinary Pharmacovigilance Market Report Highlights:

  • One of the key trends in the veterinary pharmacovigilance market is the adoption of new technologies such as electronic reporting systems and data analytics tools. These technologies allow for more efficient and accurate monitoring of adverse events, and can help to identify potential safety issues before they become more serious.
  • The software segment dominated the global veterinary pharmacovigilance industry and accounted for the largest revenue share of 51.0% in 2024
  • By product, anti-infectives held the largest share of over 45.4% of the market in 2024. Biologics segment on the other hand, is estimated to grow at the highest rate of over 14% over the next few years.
  • The in-house segment led the market with the largest revenue share of 54.4% in 2024
  • Dogs in veterinary pharmacovigilance industry held the dominant position with the highest revenue share of 50.0% in 2024
  • North America dominated the market by region in 2024 with a share of about 40%. Asia Pacific region is estimated to grow at the fastest rate of over 15.4% from 2025 to 2030.
  • The veterinary pharmacovigilance market presents significant opportunities for companies that are able to innovate, differentiate themselves, and respond to the evolving needs of the animal health industry.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Solution
    • 1.2.2. Type
    • 1.2.3. Product
    • 1.2.4. Animal Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Veterinary Pharmacovigilance Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Veterinary Pharmacovigilance Market: Solution Business Analysis

  • 4.1. Solution Market Share, 2024 & 2030
  • 4.2. Solution Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Solution, 2018 to 2030 (USD Million)
  • 4.4. Software
    • 4.4.1. Software Market, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Veterinary Pharmacovigilance Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. In-house
    • 5.4.1. In-house Market, 2018 - 2030 (USD Million)
  • 5.5. Contract Outsourcing
    • 5.5.1. Contract Outsourcing Market, 2018 - 2030 (USD Million)

Chapter 6. Veterinary Pharmacovigilance Market: Product Business Analysis

  • 6.1. Product Market Share, 2024 & 2030
  • 6.2. Product Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 6.4. Biologics
    • 6.4.1. Biologics Market, 2018 - 2030 (USD Million)
  • 6.5. Anti-Infective
    • 6.5.1. Anti-Infective Market, 2018 - 2030 (USD Million)
  • 6.6. Other Product
    • 6.6.1. Other Product Market, 2018 - 2030 (USD Million)

Chapter 7. Veterinary Pharmacovigilance Market: Animal Type Business Analysis

  • 7.1. Animal Type Market Share, 2024 & 2030
  • 7.2. Animal Type Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Animal Type, 2018 to 2030 (USD Million)
  • 7.4. Dogs
    • 7.4.1. Dogs Market, 2018 - 2030 (USD Million)
  • 7.5. Cats
    • 7.5.1. Cats Market, 2018 - 2030 (USD Million)
  • 7.6. Other Animal Types
    • 7.6.1. Other Animal Types Market, 2018 - 2030 (USD Million)

Chapter 8. Veterinary Pharmacovigilance Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Veterinary Pharmacovigilance Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Veterinary Pharmacovigilance Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.5.2. Germany
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. Germany Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. UK
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. UK Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Denmark Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Sweden Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Norway Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Veterinary Pharmacovigilance Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. Australia Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. South Korea Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Veterinary Pharmacovigilance Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Veterinary Pharmacovigilance Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Veterinary Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. ArisGlobal
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Accenture
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Ennov
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Sarjen Systems Pvt. Ltd.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Pharsafer Associates Limited
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Knoell
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Biologit
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Indivirtus
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Azierta Contract Science Support Consulting
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Oy Medfiles Ltd.
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦